*market cap above based on the number of quoted shares (i.e. non-escrow stock)
NOX CEO talks about March 2018 ESMO TAT Conference Clinical Trial Interim data
To receive email responses and updates from Noxopharm Limited, simply fill in your details using the form below.
Which of the following group do you best fit?
Do you currently hold shares in this Company?